^
    Back
    Association details:
    Biomarker:ER positive
    Cancer:Estrogen Receptor Positive Breast Cancer
    Drug:Kisqali (ribociclib) (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole

    Excerpt:
    ...- ER-positive (defined by ER-pos....
    Trial ID:
    NEOLETRIB
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO-BC-I 2020
    Title:

    LBA1 - Interim results of a phase I/Ib study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib (RIB) or alpelisib (ALP) in patients with ER+ breast cancer (BC) who had progressed after endocrine therapy (ET)

    Published date:
    05/24/2020
    Excerpt:
    LSZ plus RIB or ALP showed manageable safety and encouraging clinical activity in heavily pre-treated ER+ BC pts, regardless of ESR1 and PIK3CA mutations.
    Secondary therapy:
    LSZ102
    Trial ID:
    NCT02734615
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    CDK4/6 inhibitor-mediatated radiosensitization of estrogen receptor positive breast cancer

    Published date:
    05/15/2020
    Excerpt:
    Palbociclib significantly radiosensitized ER+ cell lines at concentrations at or below the IC50 value in clonogenic survival assays (MCF-7 rER: 1.22-1.52, T47D rER: 1.23-1.50) and led to a decrease in the surviving fraction of cells at 2 Gy (p < 0.001). Similar results were observed in ribociclib- (rER: 1.08 - 1.68) and abemaciclib-treated (rER: 1.19 - 2.05) cells....Our data suggests that CDK4/6 inhibitor-mediated radiosensitization may be effective in ER+ breast cancers prior to the development of CDK4/6 inhibitor resistance.